Yang Yongqiang, Wang Zi, Weng Lian, Fei Jun, Li Zhong
Department of Orthopaedics, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.
Department of Orthopaedics, Longmatan District People's Hospital, Luzhou, Sichuan 646600, P.R. China.
Int J Oncol. 2025 Nov;67(5). doi: 10.3892/ijo.2025.5799. Epub 2025 Sep 12.
Cancers are not merely composed of tumor cells; rather, they constitute a complex tumor microenvironment (TME) comprising diverse cell types and noncellular factors. Extracellular matrix (ECM) represents a critical component of the TME. Fibulin2 participates in ECM formation in various tumors, and its altered expression in multiple malignancies can affect tumor cell proliferation and invasiveness. Additionally, Fibulin2 has emerged as a potential biomarker in various cancer types and serves a pivotal role in tumor progression. Consequently, therapeutic strategies targeting Fibulin2 hold considerable promise. However, the research and development of Fibulin2‑targeted therapeutics has progressed at a relatively slow pace. Therefore, the roles and mechanisms of Fibulin2 in various malignancies, along with investigations into its utility as a biomarker, are comprehensively discussed in the present review. This may provide valuable guidance for the clinical translation and application of Fibulin2‑targeted therapies, and the utilization of Fibulin2 as a predictive biomarker.
癌症不仅仅由肿瘤细胞组成；相反，它们构成了一个复杂的肿瘤微环境（TME），其中包括多种细胞类型和非细胞因子。细胞外基质（ECM）是TME的一个关键组成部分。纤连蛋白2参与多种肿瘤的ECM形成，其在多种恶性肿瘤中的表达改变会影响肿瘤细胞的增殖和侵袭性。此外，纤连蛋白2已成为多种癌症类型中的潜在生物标志物，并在肿瘤进展中起关键作用。因此，针对纤连蛋白2的治疗策略具有很大的前景。然而，针对纤连蛋白2的治疗药物的研发进展相对缓慢。因此，本综述全面讨论了纤连蛋白2在各种恶性肿瘤中的作用和机制，以及对其作为生物标志物的效用的研究。这可能为针对纤连蛋白2的治疗方法的临床转化和应用，以及将纤连蛋白2用作预测性生物标志物提供有价值的指导。
